España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Exelixis
EXEL
NASDAQ
Watchlist
Leave a Comment
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$22.53
-0.07
-0.31%
Last update: 3:41 PM
15 minutes delayed
Get Report
Comment
Exelixis (EXEL) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Exelixis (NASDAQ:EXEL) Stock
Exelixis Stock (NASDAQ: EXEL)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, May 31, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
Avi Kapoor
Friday, May 24, 2024
Director At Exelixis Sells $576K Of Stock
Benzinga Insights
Monday, May 20, 2024
Exelixis Settles With Cipla To Resolve Two Pa...
Benzinga Newsdesk
Tuesday, May 14, 2024
Stephens & Co. Initiates Coverage On Exelixis...
Benzinga Newsdesk
Friday, May 10, 2024
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Vandana Singh
Friday, May 03, 2024
HC Wainwright & Co. Reiterates Buy on Exelixi...
Benzinga Newsdesk
Wednesday, May 01, 2024
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
Benzinga Insights
TD Cowen Maintains Buy on Exelixis, Raises Pr...
Benzinga Newsdesk
Exelixis shares are trading lower after the c...
Benzinga Newsdesk
Tuesday, April 30, 2024
Exelixis Maintains FY24 Financial Guidance, T...
Benzinga Newsdesk
Exelixis shares are trading lower after the c...
Benzinga Newsdesk
Exelixis Q1 2024 Adj EPS $0.17 Misses $0.24 E...
Benzinga Newsdesk
Thursday, April 11, 2024
Exelixis shares are trading lower after Barcl...
Benzinga Newsdesk
Barclays Downgrades Exelixis to Equal-Weight,...
Benzinga Newsdesk
Wednesday, April 10, 2024
What Analysts Are Saying About Exelixis Stock
Benzinga Insights
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Friday, February 23, 2024
Around $4M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Avi Kapoor
Wednesday, February 07, 2024
RBC Capital Maintains Outperform on Exelixis,...
Benzinga Newsdesk
Tuesday, February 06, 2024
Recap: Exelixis Q4 Earnings
Benzinga Insights
Exelixis Q4 Adj EPS $0.33 Beats $0.22 Estimat...
Benzinga Newsdesk
Earnings Scheduled For February 6, 2024
Benzinga Insights
Monday, February 05, 2024
Earnings Preview For Exelixis
Benzinga Insights
Friday, February 02, 2024
Stifel Maintains Hold on Exelixis, Raises Pri...
Benzinga Newsdesk
Tuesday, January 30, 2024
Breaking Down Exelixis: 7 Analysts Share Their Views
Benzinga Insights
Barclays Maintains Overweight on Exelixis, Ra...
Benzinga Newsdesk
Thursday, January 25, 2024
Exelixis Announces Detailed Results Of Phase ...
Benzinga Newsdesk
Tuesday, January 23, 2024
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
Vandana Singh
Monday, January 22, 2024
Bristol-Myers Squibb Announced Opdivo In Combination With Cabometyx Demonstrates Long-term Survival Benefits After Four Years Of Follow-up In The Checkmate -9er Trial In First-line Advanced Renal Cell Carcinoma
Charles Gross
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
Thursday, January 18, 2024
European Patent Office Rules In Favor Of Exel...
Benzinga Newsdesk
Friday, January 12, 2024
Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell'
Avi Kapoor
Monday, January 08, 2024
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
Vandana Singh
Exelixis shares are trading lower after the c...
Benzinga Newsdesk
Sunday, January 07, 2024
Exelixis Announces Reducing Its Workforce By ...
Benzinga Newsdesk
Exelixis Announces The Board Of Directors Has...
Benzinga Newsdesk
Exelixis Announces Preliminary FY23 Financial...
Benzinga Newsdesk
Tuesday, December 19, 2023
BTIG Initiates Coverage On Exelixis with Buy ...
Benzinga Newsdesk
Friday, December 15, 2023
Citigroup Initiates Coverage On Exelixis with...
Benzinga Newsdesk
Thursday, December 14, 2023
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Wednesday, December 13, 2023
6 Analysts Have This to Say About Exelixis
Benzinga Insights
RBC Capital Reiterates Outperform on Exelixis...
Benzinga Newsdesk
Monday, December 04, 2023
Exelixis Initiates STELLAR-305 Phase 2/3 Pivo...
Benzinga Newsdesk
Exelixis And Arcus Biosciences Announce Clini...
Benzinga Newsdesk
Monday, November 13, 2023
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Friday, November 10, 2023
Exelixis Announces Results From Expansion Coh...
Benzinga Newsdesk
Thursday, November 02, 2023
Where Exelixis Stands With Analysts
Benzinga Insights
Morgan Stanley Maintains Equal-Weight on Exel...
Benzinga Newsdesk
Wednesday, November 01, 2023
Exelixis Sees FY23 Revenue $1.825B-$1.850B Vs...
Benzinga Newsdesk
Exelixis Q3 2023 Adj. EPS $0.10 Misses $0.11 ...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
